This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Fintel reports that on June 3, 2025, JMP Securities downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...

The health industry witnesses significant developments as Hims & Hers acquires UK startup Zava, Sanofi plans a $9.5 billion ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...